Medroxyprogesterone Acetate Injection, Suspension
NDC Package 66993-370-83

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Medroxyprogesterone Acetate injection is a medication used to prevent pregnancy. This formulation utilizes a injection, suspension delivery system. Marketed by Prasco Laboratories, this product is identified by NDC 66993-370 and is authorized under FDA application NDA020246.

Identification & Billing

NDC Package Code
66993-370-83
Package Description
1 VIAL in 1 CARTON / 1 mL in 1 VIAL
Product Code
66993-370
11-Digit Billing Format
66993037083
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk
  • RxCUI: 1000126 - medroxyPROGESTERone acetate 150 MG in 1 ML Injection
  • RxCUI: 1000126 - 1 ML medroxyprogesterone acetate 150 MG/ML Injection
  • RxCUI: 1000126 - medroxyprogesterone acetate 150 MG per 1 ML Injection
  • RxCUI: 1000153 - medroxyPROGESTERone acetate 150 MG in 1 ML Prefilled Syringe
  • RxCUI: 1000153 - 1 ML medroxyprogesterone acetate 150 MG/ML Prefilled Syringe

Clinical Specifications

Proprietary Name
Medroxyprogesterone Acetate
Non-Proprietary Name
Medroxyprogesterone Acetate
Substance Name
Medroxyprogesterone Acetate
Dosage Form
Injection, Suspension - A liquid preparation, suitable for injection, which consists of solid particles dispersed throughout a liquid phase in which the particles are not soluble. It can also consist of an oil phase dispersed throughout an aqueous phase, or vice-versa.
Administration Route
Intramuscular - Administration within a muscle.
Active Ingredient(s)
MEDROXYPROGESTERONE ACETATE 150 mg/mL
Pharmacologic Class
Usage Information
This medication is used to prevent pregnancy. Medroxyprogesterone is like a natural hormone made by the body. It works mainly by preventing the growth and release of an egg (ovulation) during your menstrual cycle. It also makes vaginal fluid thicker to help prevent sperm from reaching an egg (fertilization) and changes the lining of the uterus (womb) to prevent attachment of a fertilized egg. Medroxyprogesterone is also used to treat endometriosis. It works by lowering the amount of certain hormones in the body and decreasing the growth of abnormal tissues that cause endometriosis. This helps reduce pain and other symptoms. Using this medication does not protect you or your partner against sexually transmitted diseases (such as HIV, gonorrhea, chlamydia).

Regulatory & Marketing

Labeler Name
Prasco Laboratories
Product Type
Human Prescription Drug
FDA Application #
NDA020246
Marketing Category
NDA AUTHORIZED GENERIC - A product marketed as a "generic" drug under an approved New Drug Application (NDA), rather than an Abbreviated New Drug Application (ANDA),.
Start Marketing Date
07-06-2021
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (66993-370). Click a package code to view its specific billing and regulatory data.

66993-370-25
25 VIAL in 1 CARTON / 1 mL in 1 VIAL

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 66993-370-83 identifies a specific commercial package of 1 vial in 1 carton / 1 ml in 1 vial of Medroxyprogesterone Acetate, a human prescription drug labeled by Prasco Laboratories. This injection, suspension is formulated for intramuscular use and contains medroxyprogesterone acetate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Prasco Laboratories on July 06, 2021. The current certification is valid through December 31, 2027.

What are the primary indications for this medication?

This medication is used to prevent pregnancy. Medroxyprogesterone is like a natural hormone made by the body. It works mainly by preventing the growth and release of an egg (ovulation) during your menstrual cycle. It also makes vaginal fluid thicker to help prevent sperm from reaching an egg (fertilization) and changes the lining of the uterus (womb) to prevent attachment of a fertilized egg. Medroxyprogesterone is also used to treat endometriosis. It works by lowering the amount of certain hormones in the body and decreasing the growth of abnormal tissues that cause endometriosis. This helps reduce pain and other symptoms. Using this medication does not protect you or your partner against sexually transmitted diseases (such as HIV, gonorrhea, chlamydia).

How is this Prasco Laboratories product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 66993037083. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
66993-370-83
11-Digit CMS (5-4-2)
66993-0370-83

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.